Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neoadjuvant Radiochemotherapy in Local Advanced Squamous Cell Carcinoma of the Esophagus With Weekly Cetuximab Plus Oxaliplatin Plus Continuous IV. 5-FU [fluorouracil] and Conventional Fractionated External Multi-Field Irradiation up to 45 Gray. A Phase I/II Study

Trial Profile

Neoadjuvant Radiochemotherapy in Local Advanced Squamous Cell Carcinoma of the Esophagus With Weekly Cetuximab Plus Oxaliplatin Plus Continuous IV. 5-FU [fluorouracil] and Conventional Fractionated External Multi-Field Irradiation up to 45 Gray. A Phase I/II Study

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab; Fluorouracil; Oxaliplatin
  • Indications Oesophageal cancer
  • Focus Therapeutic Use

Most Recent Events

  • 01 May 2014 Biomarkers information updated
  • 07 Aug 2012 Planned end date 1 May 2015 added as reported by ClinicalTrials.gov.
  • 07 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top